Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

Kidney Precision Medicine Project Central Hub (U24 Clinical Trial Not Allowed)

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

N/A

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
Office AddressUS
Contacts

Full Description

Show more
This Notice of Funding Opportunity (NOFO) requests applications for the Kidney Precision Medicine Project (KPMP) - Central Hub (CH) to support the KPMP cohort, collect and de-identify all existing and new clinical data and samples, and provide scientific, infrastructure, quality control, project management, and administrative support. The CH will collaborate with the Recruitment Sites (RS), Tissue Interrogation Sites (TIS), and Kidney Tissue Atlas Coordinating Center (KTACC) to obtain and evaluate kidney biopsies from participants with acute kidney injury (AKI) or chronic kidney disease (CKD), create a Kidney Tissue Atlas, define disease subgroups, and identify critical cells, interstitial components, pathways, and targets for novel therapies.